# Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

- Source: PR Newswire
- Published: 2026-10-24T06:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/lilly-presents-first-clinical-data-in-platinum-sensitive-ovarian-cancer-for-its-investigational-next-generation-fr-targeting-adc-at-esmo-2026-302918153.html
- Canonical: https://groundlevelnews.com/story/lilly-presents-first-clinical-data-in-platinum-sensitive-ovarian-cance-624aaa/

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FRα expression levels Clinical activity with Sofe-M was maintained even in patients with prior PARP...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._